HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MDXG
MiMedx Group, Inc.
MDXG lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MDXG Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
MDXG's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MDXG PE Valuation
MDXG has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MDXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MDXG's earnings to grow and its profitability to improve, but its revenue to decline.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over MDXG on earnings, with more consistent year-over-year improvement.
MDXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.07 | — |
| Q3 2026 | -$0.13 | -148% |
| Q2 2026 | $0.04 | -81% |
| Q1 2026 | $0.20 | -26% |
| Q4 2025 | $0.32 | +14% |
| Q3 2025 | $0.27 | -55% |
| Q2 2025 | $0.21 | -66% |
| Q1 2025 | $0.27 | -45% |
| Q4 2024 | $0.28 | -24% |
MDXG has swung to a loss: it lost $0.13 per share over the past year, after a profit the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MDXG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over MDXG on profitability, with a higher operating margin.
MDXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | -45% |
| Q2 2026 | $64.4M | -35% |
| Q1 2026 | $59M | -33% |
| Q4 2025 | $118.1M | +27% |
| Q3 2025 | $113.7M | +35% |
| Q2 2025 | $98.6M | +13% |
| Q1 2025 | $88.2M | +4.1% |
| Q4 2024 | $92.9M | +7% |
MDXG's revenue is shrinking: $62M last quarter, down 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -19% | -38 points |
| Q2 2026 | -29% | -41 points |
| Q1 2026 | -27% | -37 points |
| Q4 2025 | 18% | +6 points |
| Q3 2025 | 20% | +6.2 points |
| Q2 2025 | 13% | -14 points |
| Q1 2025 | 9.3% | -6.2 points |
| Q4 2024 | 12% | -19 points |
MDXG's operating margin was −19% last quarter, down 38 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MDXG on cash flow, with more consistent year-over-year improvement.
MDXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9M | -87% |
| Q2 2026 | -$10M | -169% |
| Q1 2026 | $1.9M | -65% |
| Q4 2025 | $25M | +33% |
| Q3 2025 | $29.3M | +49% |
| Q2 2025 | $14.4M | -34% |
| Q1 2025 | $5.3M | -11% |
| Q4 2024 | $18.8M | +91% |
MDXG generated $21M in free cash flow over the past year, down 69% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MDXG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MDXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -1.9M shares |
| 1 year | -2.6% | -3.8M shares |
| 3 years | +22% | +26.5M shares |
| 5 years | +32% | +35.1M shares |
| Available history | +36% | +38.9M shares |
MDXG has 146M diluted shares, down 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $304,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MDXG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -10.1x | Net Cash |
| Q1 2026 | -3.4x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -0.9x | Net Cash |
MDXG has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MDXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.1 | Oversold |
| Stochastic | 15.2 | Oversold |
MDXG's weekly RSI is 28 (oversold) and its Stochastic is 15 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MDXG PE vs Healthcare Sector
| Metric | MDXG | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 92 | 29 | 63 pts above |
MDXG has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MDXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.09 | 21% below |
| 20 week MA | $4.24 | 24% below |
| 50 week MA | $4.52 | 28% below |
| 100 week MA | $5.92 | 45% below |
| 200 week MA | $6.31 | 49% below |
MDXG is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over MDXG on returns for 2026, with the stronger performance.
MDXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.25 | $9.40 | +30% |
| 2021 | $9.40 | $6.49 | -31% |
| 2022 | $6.49 | $2.77 | -57% |
| 2023 | $2.77 | $8.77 | +217% |
| 2024 | $8.77 | $9.42 | +7.4% |
| 2025 | $9.42 | $6.90 | -27% |
| 2026 YTD | $6.90 | $3.24 | -53% |
MDXG's yearly returns have swung widely, from +217% in 2023 to −57% in 2022. It's down 53% so far in 2026.